1 active not recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
Follow Metastatic Synovial Sarcoma: new trials by email Literature Review of Metastatic Synovial Sarcoma trials Research Report on Metastatic Synovial Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection - Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 42 | 2026-11-23 | 2026-09-25 |
| Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2017-12-14 | 2023-10-25 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
Sarcoma, Synovial (4) · Liposarcoma, Myxoid (2) · Dermatofibrosarcoma (1) · Fallopian Tube Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Melanoma (1) · Mycosis Fungoides (1) · Neurofibrosarcoma (1) · Ovarian Neoplasms (1) · Sezary Syndrome (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective Tissue (4) · Neoplasms, Connective and Soft Tissue (4) · Sarcoma (4) · Liposarcoma (2) · Neoplasms, Adipose Tissue (2) · Neoplasms, Nerve Tissue (2) · Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fibrosarcoma (1)
Biopsy (1) · Cyclophosphamide (1) · Decitabine (1) · Injections (1) · Interferon-gamma (1) · Leukapheresis (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · interferon gamma-1b (1) · pazopanib (1) · pembrolizumab (1) · sapanisertib (1)
National Cancer Institute (NCI) (3) · Roswell Park Cancer Institute (1)
United States (3)
Michael S Khodadoust, MD (1) · Michael Wagner (1) · Philip McCarthy, MD (1) · William D Tap (1)
P30CA015704 (1), P30CA016056 (1), R01CA164333 (1), U01CA154967 (1), U10CA180821 (1), UM1CA186709 (1)